Farxiga and Sputum discolored - a phase IV clinical study of FDA data

Summary:

Sputum discolored is reported as a side effect among people who take Farxiga (dapagliflozin), especially for people who are female, 50-59 old, also take Metformin, and have High blood pressure.

The phase IV clinical study analyzes which people have Sputum discolored when taking Farxiga. It is created by eHealthMe based on reports of 18,416 people who have side effects when taking Farxiga from the FDA, and is updated regularly.

What is Farxiga?

Farxiga has active ingredients of dapagliflozin. It is often used in diabetes. eHealthMe is studying from 18,798 Farxiga users. Check the latest studies of Farxiga.

What is Sputum discolored?

Sputum discolored is found to be associated with 910 drugs and 553 conditions by eHealthMe. Check the latest studies of Sputum discolored.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Aug, 26, 2026

18,416 people reported to have side effects when taking Farxiga.
Among them, 14 people (0.08%) have Sputum discolored.

Among these 14 people:

What is the gender of people who have Sputum discolored when taking Farxiga? *

female: 91.67 %
male: 8.33 %

What is the age of people who have Sputum discolored when taking Farxiga? *

What are other drugs people take besides Farxiga? *

What are other side effects people have besides Sputum discolored? *

Productive Cough: 14 people, 100.00%
Headache (pain in head): 11 people, 78.57%
Dyspnea Exertional: 11 people, 78.57%
Cough: 11 people, 78.57%
Body Mass Index Increased: 10 people, 71.43%
Hypersensitivity: 10 people, 71.43%
Weight Increased: 10 people, 71.43%
Feeling Hot: 10 people, 71.43%
Dyspnea (difficult or laboured breathing): 10 people, 71.43%
Diverticulum (out pouching of a hollow (or a fluid-filled) structure in the body): 10 people, 71.43%

What are the existing conditions these people have? *

Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 10 people, 71.43%
High Blood Pressure: 10 people, 71.43%
Ovarian Cancer (cancer of ovary): 2 people, 14.29%
Fallopian Tube Cancer (cancer of fallopian tube): 2 people, 14.29%
Uveitis (inflammation of the uvea): 1 person, 7.14%
Primary Pulmonary Hypertension (primary high blood pressure that affects the arteries in the lungs and the right side of your heart): 1 person, 7.14%
Cardiac Failure Congestive: 1 person, 7.14%
Ankylosing Spondylitis (type of arthritis affecting the spine): 1 person, 7.14%

* Approximation only. Some reports may have incomplete information.

Do you take Farxiga and have Sputum discolored?

- Check whether Sputum discolored is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Farxiga:

Farxiga (18,798 reports)

Browse all side effects of Farxiga:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Sputum discolored:

Sputum discolored (910 drugs)

Browse all the conditions that are associated with Sputum discolored:

Sputum discolored (553 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on dapagliflozin (the active ingredients of Farxiga) and Farxiga (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.